Dolor Technologies

Executive Summary

Dolor Technologies is a Salt Lake City-based medical device company addressing the significant unmet need in pain management with its proprietary SphenoCath® device. The SphenoCath is a disposable, precision intranasal drug delivery system that targets the sphenopalatine foramen to rapidly block nerve signals and provide relief for various headache and pain conditions. By offering a needle-free alternative to traditional injections, the device aims to improve patient comfort and accessibility in both clinical and at-home settings. The company focuses on providing healthcare providers with a tool to administer medications locally, potentially reducing systemic side effects and onset times. With a growing body of clinical evidence supporting its efficacy, Dolor Technologies is positioned to capture market share in the expanding field of interventional pain management.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Expanded Indications (e.g., Migraine or Chronic Pain)70% success
• Q1 2027Publication of Pivotal Clinical Trial Results in Peer-Reviewed Journal80% success
• Q4 2026Strategic Partnership or Distribution Agreement with Major Healthcare Provider50% success